PhaseBio Pharmaceuticals, Inc. (PHAS) financial statements (2021 and earlier)

Company profile

Business Address 1 GREAT VALLEY PARKWAY
MALVERN, PA 19355
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments287461
Cash and cash equivalents287461
Restricted cash and investments  0
Receivables 10
Other undisclosed current assets1241
Total current assets:407963
Noncurrent Assets
Operating lease, right-of-use asset22
Property, plant and equipment820
Other noncurrent assets000
Total noncurrent assets:1040
TOTAL ASSETS:508263
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1065
Accounts payable432
Accrued liabilities633
Debt52 
Total current liabilities:1585
Noncurrent Liabilities
Long-term debt and lease obligation8148
Long-term debt, excluding current maturities7128
Operating lease, liability22
Liabilities, other than long-term debt5200
Deferred rent credit  0
Other liabilities10 
Derivative instruments and hedges, liabilities52  
Total noncurrent liabilities:61148
Total liabilities:762312
Stockholders' equity
Stockholders' equity attributable to parent(25)6051
Common stock000
Treasury stock, value(0)(0)(0)
Additional paid in capital236222174
Accumulated deficit(261)(162)(123)
Total stockholders' equity:(25)6051
TOTAL LIABILITIES AND EQUITY:508263

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:021
Operating expenses(85)(42)(20)
Operating loss:(85)(40)(20)
Nonoperating income (expense)(13)0(4)
Other nonoperating income (expense)(14)0(4)
Interest and debt expense(1)(1)(4)
Loss before gain (loss) on sale of properties:(100)(40)(28)
Other undisclosed net income114
Net loss available to common stockholders, diluted:(99)(39)(24)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(99)(39)(24)
Comprehensive loss, net of tax, attributable to parent:(99)(39)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: